Clinical studies are essential to validate our innovations and ensure that they meet the highest standards. They allow us to assess the performance and reliability of our devices, optimise our solutions using robust data, compare their performance with reference methods, and evaluate their health-economic benefits.
Découvrez les études conduites avec nos partenaires pour évaluer VisioCyt® Bladder et faire progresser la prise en charge du cancer de la vessie.
To develop an algorithm capable of distinguishing cancerous from non-cancerous urothelial cells, and to assess the sensitivity and specificity of VisioCyt® Bladder using urine samples.
To assess the negative predictive value (NPV) and sensitivity of urine testing with VisioCyt® Bladder in real-world clinical practice.
To demonstrate the clinical value of VisioCyt® Bladder compared with conventional urine cytology for detecting recurrence in patients under surveillance for high- or very-high-risk non-muscle-invasive bladder cancer.
To improve understanding of the treatment and follow-up of NMIBC, and to assess biomarkers in real-world clinical practice that could ultimately reduce unnecessary cystoscopies and improve patient comfort.
